Last reviewed · How we verify
UPA-ECx2
UPA-ECx2 is an uPA (urokinase plasminogen activator) inhibitor conjugate designed to target and inhibit fibrinolysis and cell migration pathways.
At a glance
| Generic name | UPA-ECx2 |
|---|---|
| Also known as | ella, ella-one |
| Sponsor | Oregon Health and Science University |
| Target | uPA (urokinase plasminogen activator) |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
UPA is a serine protease involved in plasminogen activation, fibrin degradation, and cell migration. By inhibiting uPA activity, UPA-ECx2 may reduce pathological fibrinolysis and cellular invasion. The ECx2 designation suggests an engineered or conjugated formulation, though specific structural details are limited in public literature.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |